Erythropoiesis is a process during which multipotential hematopoietic stem cells proliferate, differentiate and eventually form mature erythrocytes. Interestingly, unlike most cell types, an important feature of erythropoiesis is that following each mitosis the daughter cells are morphologically and functionally different from the parent cell from which they are derived, demonstrating the need to study erythropoiesis in a stage-specific manner. This has been impossible until recently due to lack of methods for isolating erythroid cells at each distinct developmental stage. This review summarizes recent advances in the development of methods for isolating both murine and human erythroid cells and their applications. These methods provide powerful means for studying normal and impaired erythropoiesis associated with hematological disorders.
As a part of the hematopoiesis, erythropoiesis includes the whole process in which the multipotential hematopoietic stem cells develop into mature red cells within the hematopoietic microenvironment [1] . Although this process is a continuum, it can be functionally divided into two major steps namely early stage erythropoiesis and terminal erythroid differentiation. During early stage erythropoiesis, HSCs are committed to early stage erythroid progenitor burst-forming unit-erythroid cells (BFU-E) which further differentiate to late stage erythroid progenitor colonyforming unit-erythroid (CFU-E) cells. During terminal erythroid differentiation, CFU-E cells undergo 4-5 mitoses to sequentially become proerythroblast (Pro-E), basophilic erythroblast (Baso-E), polychromatic erythroblast (Poly-E) and orthochromatic erythroblasts (Ortho-E) which expel nucleus to generate enucleated reticulocytes.
Disordered or ineffective erythropoiesis is a feature of a large number of human hematological disorders. These include Cooley's anemia [2-5], congenital dyserythropoietic anemia's (CDA) [6-8], Diamond-Blackfan Anemia (DBA) [9, 10] , malarial anemia [11] [12] [13] and various bone marrow failure syndromes such as myelodysplastic syndromes (MDS) [14] [15] [16] . It is very likely that more human diseases associated with disordered erythropoiesis will be uncovered in the future. Thus, a detailed understanding of the process of erythropoiesis is of both biological and clinical significance.
Furthermore, it is interesting to note that dyserythropoiesis manifests itself at different developmental stages in these disorders with defects in erythroid progenitors observed primarily in DBA [17, 18] , cytokinesis/enucleation defects in congenital dyserythropoietic anemia type I-III (CDA I-III) [19] [20] [21] [22] , and apoptosis of terminally differentiating cells in Cooley's anemia and MDS [23] [24] [25] [26] [27] . These findings suggest that different dyserythropoietic disorders are driven by perturbations in normal gene expression patterns at distinct developmental stages. Identification of stage-specific defects and molecular pathways will not only yield signifi-cant mechanistic insights into the cellular basis for ineffective erythropoiesis but also help to design therapeutic strategies for improving clinical management of patients.
Despite the importance of studying erythropoiesis in a stage-specific manner, this has not been possible until recently. In the recent five years, great efforts have been made in developing novel methods for studying normal and abnormal erythropoiesis [28] [29] [30] [31] . The development of these optimal methods and their applications are summarized in this review.
Method for solation of murine erythroid progenitor BFU-E and CFU-E cells
Traditionally, the erythroid progenitor BFU-E and CFU-E cells have been defined by colony assays [32] [33] [34] [35] [36] [37] . With the aim to find small molecules that can stimulate erythropoiesis earlier than erythropoietin and enhance CFU-E production, Prof. Lodish's group [38] firstly established a method to purify erythroid progenitor cells from mouse E14.5-E15.5 fetal liver. Briefly, fetal liver cells were stained with biotin-conjugated antibodies against murine Ter119, B220, Mac-1, CD3 (cluster of differentiation 3), Gr-1, Sca-1, CD16/CD32, CD41 and CD34, then the biotin-negative fraction was stained with APC-CD117 (c-Kit) and FITC-CD71 (transferrin receptor) and within the Kit + fraction, the level of CD71 expression was used to separate BFU-E (CD71 10%low ) and CFU-E (CD71 20%high ). The purity of isolated BFU-E (Kit + /CD71 10%low ) and CFU-E ((Kit + /CD71 20%high ) reached 90% [38] . The great advantage of this method is the ability to isolate pure BFU-E and CFU-E simultaneously. Using these cell populations, the authors identified compounds which promote BFU-E self-renewal [38] .
Method for isolation of murine erythroid precursors
Erythroid precursors also refer to erythroblasts which include proerythroblasts, basophilic erythroblasts, polychromatic erythroblasts and orthochromatic erythroblasts. To identify the surface markers for isolating murine erythroblasts, we examined the changes in expression pattern of more than 30 red cell membrane proteins during murine terminal erythroid differentiation. All major transmembrane and skeletal proteins increased, while those of various adhesion molecules decreased. The adhesion molecule CD44 was found to exhibit a progressive and the most dramatic decrease with more than 30-fold during erythroid differentiation from murine proerythroblast to orthochromatic erythroblast. In contrast, the expression of CD71 which was widely used to separate different stages of murine erythroid cells did not show significant change. These results strongly suggest that CD44 might be a better surface marker than CD71 for isolating murine erythroblasts at distinct developmental stage. Indeed, use of TER119 (erythroid lineage marker), CD44 and forward scatter (FSC, cell size) enabled purification of murine erythroblasts at distinct stages of terminal erythroid differentiation [28] . In contrast, the use of CD71 resulted in the mixture of various stages of erythroblasts except for a pure population of proerythroblasts [28, 39] .
Method for quantification of murine terminal erythroid differentiation
Under physiological condition, murine proerythroblast undergoes three mitoses to sequentially generate basophilic erythroblasts, polychromatic erythroblasts, and orthochromatic erythroblasts. Thus, it is presumed that during normal terminal erythroid differentiation, the ratio of Pro : Baso : Poly : Ortho should follow a 1 : 2 : 4 : 8 pattern. Liu et al. recently developed a new strategy to quantify this process in vivo [29] . Briefly, CD45
+ cells from single cell suspension of normal murine bone marrow were firstly depleted by magnetic separation. Then the CD45  cells were stained with different fluorescence conjugated antibodies, including TER119, CD44, CD45, CD11b, GR1 and the viability marker 7AAD, and analyzed by flow cytometry. Finally, the TER119, CD44 and FSC were used to gate different populations of terminally differentiated erythroid cell populations (Figure 1 ). This novel method not only enables successful in vivo quantitation of murine terminal erythroid differentiation, but also could clearly separate all murine terminally differentiating erythroid cells: Pro, Baso, Poly, Ortho erythroblasts, reticulocytes, and red blood cells. This novel method provided accurate means for studying erythroid differentiation and erythroid related disorders in mouse model [40] [41] [42] [43] [44] . Evaluating this achievement in a review, professor Palis said: this research created a novel method of realizing the separation of cell subsets through flow cytometry and the obtained cells can be used in the further research [45] .
Method for isolation of human erythroid progenitor BFU-E and CFU-E cells
While considerable progress has been made in the study of murine erythropoiesis [38, [46] [47] [48] , the knowledge on human erythropoiesis is limited. To study the process of human erythropoiesis, it is important to be able to isolate human erythroid cells at distinct stages of development. To identify the surface markers for human BFU-E and CFU-E, Li et al. [31] systematically examined the expression of surface Adapted from our published work in [29] . markers (CD34, IL-3R, CD36, CD71, CD45 and GPA (glycophorin A) during early stage of human in vitro erythropoiesis. Based on the expression profiles of these surface markers and the related colony-forming ability, the surface markers of human BFU-E were identified as CD45
low and human CFU-E markers were identified as CD45
Combining with other lineage surface markers, this method can be used to isolate BFU-E and CFU-E from primary human samples such as human bone marrow, peripheral blood and umbilical cord blood [31] . The ability to isolate highly pure human BFU-E and CFU-E progenitors should enable detailed cellular and molecular characterization of these distinct progenitor populations and define the contribution of alterations in these progenitor populations to disordered erythropoiesis in various disorders.
Method for quantification of human terminal erythroid differentiation
We used similar approaches to identify surface markers for distinguishing human erythroid precursors (erythroblasts). For this, we examined the changes in the expression of 15 surface markers during terminal differentiation of in vitro human erythropoiesis. Different from mouse, the expression of CD44 did not decrease significantly. Instead, the expression of band 3 progressively increased and that of 4 integrin decreased. The use of GPA (erythroid lineage marker, equal to TER119 in the murine system), band 3 and 4 integrin as surface markers enabled us to develop a means to isolate highly purified populations of erythroblasts at each distinct stage from an erythroid culture system and from primary human bone marrow cells (Figure 2) . Importantly, the ratio of erythroblasts at successive stage in the bone marrow followed the predicted 1 : 2 : 4 : 8 : 16 pattern. In contrast, bone marrows from myelodysplastic syndrome patients exhibited altered terminal erythroid differentiation profiles [30] . Thus, our findings offer a means of isolating and quantifying each developmental stage during terminal erythropoiesis in vivo. Our findings should facilitate a comprehensive cellular and molecular characterization of each specific developmental stage of human erythroblasts and should provide a powerful means of identifying stage-specific defects in diseases associated with pathological erythropoiesis. Prof. Koury [49] stated in his review: the definition of erythrocytes belonging to distinct stages was only by means of morphology and Giemsa staining, but now isolateing and purifying erythrocytes of distinct stages is realized  cells isolated from primary human bone marrow were stained with GPA, a4 integrin, and band 3. A, Plot of band 3 vs a4 integrin of the GPA positive cells. B, Representative cytospin images (100) of the sorted populations gated in A. Adapted from our published work in [30] .
by combining surface markers and flow cytometry. This method offers novel strategies for quantitative research and diagnoses of human erythroid related disorders [50] [51] [52] .
Transcriptional profiles during both murine and human erythropoiesis
As mentioned earlier, unlike most cell types, a distinguishing feature of erythropoiesis is that following each mitosis, the daughter cells are morphologically and functionally different from their parent cell. For example, major differences between BFU-E and CFU-E cells include different proliferative potential and dependence on erythropoietin [53, 54] . Furthermore, during terminal erythroid differentiation, the ability to undergo cell division progressively diminishes. While proerythroblasts can divide four times, orthochromatic erythroblasts do not divide at all [30] . Structural and functional differences strongly suggest the differences in gene expression profiles. Global gene expression studies of human and murine erythroid development and differentiation have been previously performed [55] [56] [57] [58] [59] [60] [61] [62] [63] . However, in most studies, cells were not purified by cell surface or other markers, but were selected at differing time points in vivo or in culture. Moreover, most studies were performed using micro array analysis. To obtain the highest quality of transcriptome data, our laboratory has utilized the highly pure erythroid cells at each distinct developmental stage in conjunction with RNA-seq [31, 64] . Our analysis uncovered the potential molecular regulation networks and revealed significant difference between human and mouse [64] . These data provide solid foundation for future studies of normal and disordered erythropoiesis.
Changes in membrane protein during maturation of reticulocytes to erythrocytes
Maturation of reticulocytes into mature erythrocytes is the last step of erythropoiesis. While it is well known that the transition of reticulocytes into erythrocytes is accompanied with dramatic changes in the structure and properties of the plasma membrane [65] [66] [67] [68] [69] , the molecular changes were poorly understood. To address this, we compared the expression of more than 30 red cell membrane proteins between reticulocytes and erythrocytes. For the cytoskeleton proteins, we found that tubulin is lost; actin, tropomyosin, and myosin are dramatically decreased; and adducin is decreased a little, while the expression of spectrin, ankyrin, 4.1R, 4.2, p55, tropomodulin, and 4.9, is not changed. For transmembrane proteins, we discover that CD71, GLUT4 (glucose transporter 4), Na/K-ATPase, and ICAM-4 (intercellular adhesion molecule-4) are largely decreased during reticulocyte maturation. GPA, CD47, Duffy, NHE1 (sodium/hydrogen exchanger 1), and Kell, are decreased slightly. However, band 3, Rh, RhAG (Rh-associated glycoprotein), GPC (glycophorin C), XK (X-Linked Kx Blood Group), are increased during reticulocyte maturation [70] . These findings laid the foundation for studying the structure and function of red cells [71, 72] , and offered strategies for examining red cell membrane proteins in various anemia models [73, 74] .
Conclusion
Recent comprehensive characterization of membrane protein changes during erythropoiesis enabled the identification of optimal surface markers and established a series of method to distinguish erythroblasts at distinct stages of maturation both for human and murine. These novel methods enable the isolation of highly purified populations of erythroblasts at distinct stages and also offer a means of detection and diagnosis stage-specific defects in erythroid related diseases in inherited and acquired red cell disorders. The transcriptional profiles during erythropoiesis provide significant resource for further functional studies. 
